Reports Q3 revenue $293.8M vs. $270.5M last year. “Through disciplined execution and steady, measurable progress, Emergent’s financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results,” said CEO Joe Papa. “We have successfully improved efficiencies and refocused our operations related to customer demand, generated value in our core medical countermeasures and NARCAN Nasal Spray businesses and refinanced our debt leading to increased revenue and cash flow. Based on the success of our efforts since the beginning of this year, we are officially entering the turnaround phase of our multi-year transformation plan, and we will be focused on driving profitable growth, continued operational improvements and the generation of sustainable value for shareholders. We believe ongoing public health crises like the opioid overdose epidemic and mpox outbreak underscore the need for Emergent’s capabilities and expertise. It is not if, but when, the next public health threat emerges, and we believe we are uniquely qualified to help respond to protect, enhance and save lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions appoints Lowry as Chief Medical Officer
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Emergent BioSolutions Grants CFO Stock for Contributions
- Emergent Biosolutions Secures Loan, Bolsters Growth Strategy
- Emergent BioSolutions closes $100M asset-backed loan facility